Ascendis Pharma A/S (NASDAQ: ASND) recently issued its shareholders an update on the third phase of its study on TransCon PTH. The company investigated the impact on the compound in adults affected with Hypoparthyrodism (HP) across the country.
TransCon PTH induced a tremendous improvement in patients
The company revealed that the clinical participants recorded a considerable improvement after receiving a dose of TransCon PTH contrasted to all crucial endpoints during its update. Ascendis terms the endpoint as the expected levels of calcium between 8.3 -10.6 mg/Dl together with traditional methods of therapy. In addition, the company’s CEO, Jan Mikkelsen, stated that the company was the first to conduct a phase 3 trial where at least three-quarters of the participants regained management of their hypoparathyroidism.
In addition, Ascendis recorded remarkable improvements in the participants’ quality of life who enrolled in the program. The disease affects several countries, including the U.S. Japan and others. The company’s shared its results on the study, recording several highlights such as the safety, efficacy, and others
Hypoparathyroidism is a unique condition that develops when the parathyroid hormone decreases, thus reducing calcium levels in the blood.
Ascendis Pharma is among the leading companies in the biotechnology industry that is administering creative means to influence several patients’ lives significantly by providing them with treatments. The company aims to develop products and services based on its technology, thus, developing effective and best-in-class therapies for its customers.
TransCon PTH is an alternative therapy for adult patients with hypoparathyroidism
The company operates in Denmark and possesses facilities in several countries, including Germany, Berlin, and the U.S. Ascendis’ recent announcement places it in a better position in the Biotechnology industry for its contribution to the development of the TransCon PTH.
The compound is an advancement of an alternative treatment method for adults affected with hypoparathyroidism. Furthermore, the company created TransCon PTH to replace a person’s PTH levels to physiologic levels for at least 24 hours, thus targeting both long and short-term impacts of the illness. The compound is among the various drugs that the regulatory bodies granted its use in countries like the U.S and Europe.
